TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15226326
Drug: Sequential doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential doxorubicin followed by docetaxel (A‐‐>T)
Study: 7832682
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (GaAlAs laser)
Study: 3276193
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with 300 mg doxycycline
Study: 28402245
Drug: Levothyroxine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (starting dose of 50 μg daily, or 25 μg if body weight <50 kg or with coronary heart disease)
Study: 10201430
Drug: Medication withdrawn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication withdrawn in one patient
Study: 31535099
Drug: Resorbable poly‐D‐L‐lactide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resorbable poly‐D‐L‐lactide foil fixed at a distance (SonicWeld Rx shell technique [SWST])
Study: 19198801
Drug: Brace treatment
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace treatment (Dresden scoliosis orthosis)
Study: 19198801
Drug: Noncompliant group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncompliant group (no brace treatment)
Study: 19198801
Drug: Compliant group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliant group (brace treatment)
Study: 16937304
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (estramustine phosphate + endocrine therapy)
Study: 16937304
Drug: Endocrine monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine monotherapy
Study: 15665929
Drug: Beta-adrenoblockers and
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenoblockers and angiotensin-converting enzyme inhibitors
Study: 9164179
Drug: Filgrastim 5
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim 5 micrograms/kg/d SC bolus injection
Study: 9164179
Drug: Filgrastim 10
Normalized name: pegfilgrastim 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim 10 micrograms/kg/d SC continuous infusion
Study: 7693314
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (topical glucocorticoid)
Study: 3297278
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with BCNU, cyclophosphamide, vincristine, and prednisone (BCVP) given every 6 weeks for an additional 18 months
Study: 17699816
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy (control group)
Study: 18330846
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) monotherapy
Study: 27218676
Drug: GS-5745 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-5745 (multiple doses: 0.3, 1.0, 2.5 or 5.0 mg/kg IV every 2 weeks or 150 mg SC weekly)
Study: 27218676
Drug: GS-5745 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-5745 (multiple doses)
Study: 22195358
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 mg/day for 3 weeks, then 10 mg/day)
Study: 19758285
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (G1) - informed treatment
Study: 19758285
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (G2) - informed possible active drug or placebo
Study: 29631553
Drug: 10-week oral
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10-week oral estrogen replacement (combination of ethinyl estradiol 0.03 mg and dienogest 2 mg)
Study: 16873437
Drug: Prebiotic oligosaccharides
Normalized name: chitosan oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic oligosaccharides (0.8 g/100 ml)
Study: 31789451
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg twice)
Study: 26642301
Drug: Saxagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin (5 mg)
Study: 20970963
Drug: 0.5% PVP-I
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% PVP-I solution (Arakeri's iodine solution)
Study: 11763939
Drug: Oral‐B CrossAction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B CrossAction toothbrush
Study: 7935276
Drug: N-acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (600 mg a day for two years)
Study: 7935276
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs (control group)
Study: 30629306
Drug: Swallowing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowing therapy program initiated within 1 year post-radiotherapy
Study: 30629306
Drug: Swallowing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowing therapy program initiated after 2 years post-radiotherapy
Study: 8679463
Drug: No perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No perioperative chemotherapy
Study: 8790128
Drug: Blood lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood lead levels greater than 0.96 mumol/L (20 micrograms/dL)
Study: 8790128
Drug: Blood lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood lead levels greater than 0.48 mumol/L (10 micrograms/dL)
Study: 1282619
Drug: Nisoldipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (10 mg twice daily)
Study: 6433495
Drug: BCAA enriched
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCAA enriched solution containing 50% of amino acids as BCAA
Study: 6433495
Drug: Complete feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete feeding solution containing 15.6% of amino acids as BCAA
Study: 10210384
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg furosemide
Study: 8533565
Drug: Misoprostol (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (administered orally 17 hours before vacuum curettage)
Study: 8533565
Drug: Misoprostol (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (administered orally 10 hours before vacuum curettage)
Study: 30293352
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose of 1.0 μg/kg, followed by continuous infusion of 0.5 μg·kg(‐1)·h(‐1) until 20 min before the end of operation)
Study: 23085116
Drug: Graded exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded exercise treatment (GET)
Study: 21389329
Drug: Transdermal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal fluid (TDF) sampling following acute plyometric exercise
Study: 21389329
Drug: Transdermal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal fluid (TDF) sampling following 60 min of cycling exercise at 60% Vo(2)(peak)
Study: 18513462
Drug: Varenicline (0.5-2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (0.5-2.0 mg/day)
Study: 14570652
Drug: IV saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV saline 5 mL (Group I)
Study: 14570652
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of IV pantoprazole (Group II)
Study: 14570652
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of IV ranitidine (Group III)
Study: 11218969
Drug: Cost-effectiveness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost-effectiveness of Atorvastatin
Study: 2458198
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (2 x 2 mg)
Study: 1563131
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with propranolol 20 mg tid and diltiazem 60 mg tid
Study: 362831
Drug: i.v. L-tryptophan
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. L-tryptophan
Study: 31295165
Drug: SBIRT (Substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBIRT (Substance Use Screening, Brief Intervention, and Referral to Treatment)
Study: 22836861
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral refeeding (EORF)
Study: 25441594
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral refeeding (CORF)
Study: 25022371
Drug: Modified oral
Normalized name: Food Starch, Modified Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified oral brush biopsy
Study: 17322145
Drug: Once-daily mesalazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily mesalazine (1 x 4 g/d)
Study: 17322145
Drug: Twice-daily mesalazine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily mesalazine (2 x 2 g/d)
Study: 11882333
Drug: 25 mg/day
Normalized name: estradiol 0.025 MG/Day Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/day TRF25
Study: 11882333
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day TRF25
Study: 11882333
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day TRF25
Study: 11882333
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day TRF25
Study: 9835980
Drug: Midazolam (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.07 mg.kg‐1, IM)
Study: 28923223
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment modalities for hepatocellular carcinoma
Study: 15218558
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg diclofenac sodium softgel
Study: 15218558
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg diclofenac potassium (Cataflam)
Study: 10845671
Drug: Prednisolone-primed IFN
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone-primed IFN treatment (Group I)
Study: 10845671
Drug: IFN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN treatment only (Group II)
Study: 1302763
Drug: 16.4 mg
Normalized name: rabacfosadine 16.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16.4 mg iv prednisolone
Study: 1302763
Drug: 49.2 mg
Normalized name: fusidate 49.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 49.2 mg iv prednisolone
Study: 1302763
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug (baseline)
Study: 3886139
Drug: Fentiazac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentiazac (100 mg QID)
Study: 3886139
Drug: Paracetamol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (500 mg QID)
Study: 22892722
Drug: Ultra-low-dose chest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose chest computed tomography (ULD-CT) with model-based iterative reconstruction (MBIR)
Study: 22892722
Drug: Ultra-low-dose chest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose chest computed tomography (ULD-CT)
Study: 22892722
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose diagnostic CT (SDD-CT)
Study: 22892722
Drug: Low-dose diagnostic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose diagnostic CT (LDD-CT)
Study: 16841343
Drug: Fluoxetine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (up to 40 mg)
Study: 11321183
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) and interferon‐alpha (IFN‐alpha) combination therapy at high dose (600 mg ZDV/6 MIU IFN‐alpha)
Study: 11321183
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) and interferon‐alpha (IFN‐alpha) combination therapy
Study: 11321183
Drug: Interferon‐alpha (IFN‐alpha)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐alpha (IFN‐alpha) monotherapy
Study: 2905069
Drug: Acetazolamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (500 mg daily)
Study: 17255240
Drug: Mass oral
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass oral azithromycin distribution
Study: 21277016
Drug: simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 40 mg daily
Study: 20525840
Drug: Glucosamine 500
Normalized name: glucosamine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine 500 mg three times daily
Study: 8252691
Drug: Combined supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined supplementation with alpha-tocopherol (800 IU/d), ascorbate (1.0 g/d), and beta carotene (30 mg/d)
Study: 30145512
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Cognitive-Behavioral Therapy and Fluoxetine (COMB)
Study: 22490589
Drug: Dexmedetomidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1.0 µg/kg over 10 minutes, maintenance dosage 0.7 µg×kg(‐1)×h(‐1))
Study: 17426069
Drug: Propofol target-controlled
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target-controlled infusion
Study: 15978305
Drug: Pheniramine maleate
Normalized name: Pheniramine Maleate
DrugBank: Pheniramine (DB01620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pheniramine maleate 0.3%/naphazoline hydrochloride 0.025% ophthalmic solution
Study: 12416598
Drug: 2 mg/day
Normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/day of risperidone
Study: 12416598
Drug: 4 mg/day
Normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/day of risperidone
Study: 10599225
Drug: Conventional drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drugs used in acute destructive pancreatitis
Study: 1481179
Drug: Inhaled frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled frusemide (40 mg) with placebo pretreatment
Study: 1481179
Drug: Inhaled frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled frusemide (40 mg) with indomethacin pretreatment
Study: 1481179
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation with placebo pretreatment
Study: 1481179
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation with indomethacin pretreatment
Study: 30821897
Drug: Synbiotic supplement
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplement
Study: 18622139
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 200 mcg once daily
Study: 15767334
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (3 g daily, providing 1,200 mg of calcium)
Study: 10524689
Drug: anti-TNFα monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-TNFα monoclonal antibody treatment
Study: 7733079
Drug: Pentasa (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentasa (1 g/day)
Study: 7733079
Drug: Cortenema (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortenema (100 mg/day)
Study: 1345695
Drug: Preoperative artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative artificial feeding (enteral or parenteral) for 7 to 15 days
Study: 29231363
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy group (laser and ultrashort wave treatment)
Study: 25064594
Drug: Regular paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular paracetamol (3990 mg/day, three times per day)
Study: 25064594
Drug: As-needed paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed paracetamol (maximum 4000 mg/day)
Study: 25064594
Drug: Regular paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular paracetamol vs placebo
Study: 25064594
Drug: As-needed paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed paracetamol vs placebo
Study: 25064594
Drug: Regular paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular paracetamol vs as-needed
Study: 15752407
Drug: Ranitidine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 50 mg every 8 hours
Study: 9631989
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg once weekly
Study: 12161404
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg/day for 7 days followed by fluconazole 150 mg once weekly
Study: 7819037
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (3,000 mg)
Study: 2080484
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg prazepam tablets
Study: 26091386
Drug: 5% dapsone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dapsone gel
Study: 24999283
Drug: Problematic drug
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problematic drug use identification
Study: 24999283
Drug: Correlates of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlates of problematic drug use
Study: 7865641
Drug: Amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 500 mg q.d.s. before meals
Study: 7865641
Drug: Amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 500 mg q.d.s. after meals
Study: 7865641
Drug: Amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 500 mg q.d.s. before meals (good compliers)
Study: 7865641
Drug: Amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 500 mg q.d.s. after meals (good compliers)
Study: 1106446
Drug: Temazepam (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (15, 20, or 30 mg in hard gelatin capsules or 20 mg in soft gelatin capsules)
Study: 28790412
Drug: Directed degeneration
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directed degeneration method for investigating ligand recognition mechanisms of endothelin receptor type A (ETA) with endothelin-1 (ET-1)
Study: 22165032
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with oral lefoxidine 0.2 mg three times daily after recovery from anesthesia
Study: 12393732
Drug: PCV7 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV7 vaccine administered before transplantation and at 3 months, 6 months, and 12 months post-transplantation
Study: 12393732
Drug: No vaccine
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vaccine administered before transplantation
Study: 11246617
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (15 mg/day)
Study: 9065635
Drug: Oral emedastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral emedastine difumarate
Study: 9065635
Drug: Xiao qing
Normalized name: Xiao mai
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiao qing long tang (homeopathic decongestant)
Study: 9065635
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate aqueous nasal spray
Study: 9065635
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pre-treatment measurements)
Study: 2949309
Drug: Intravenous ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketoprofen (100 mg in 5 ml)
Study: 2949309
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 ml)
Study: 29497812
Drug: 2-L polyethylene
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L polyethylene glycol with ascorbic acid (PEG/Asc)
Study: 27391495
Drug: Mini-plate-anchored face-mask
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-plate-anchored face-mask therapy (n = 5)
Study: 18446020
Drug: Vit/Min plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vit/Min plus 4.5 g FOS plus 200 mg fish oil-derived DHA (DHA-FOS group)
Study: 18446020
Drug: Basic vitamin-mineral
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic vitamin-mineral supplement (Vit/Min group)
Study: 18446020
Drug: Vit/Min plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vit/Min plus 4.5 g fructo-oligosaccharide (FOS group)
Study: 16339289
Drug: Once-monthly ibandronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-monthly ibandronate (150 mg)
Study: 16339289
Drug: Once-monthly ibandronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-monthly ibandronate (100 mg)
Study: 16339289
Drug: Once-monthly ibandronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-monthly ibandronate (50 mg)